文献速递消化内镜消化道肿瘤与早癌

分块结肠内镜黏膜切除术后的腺瘤复发可预测:悉尼EMR复发工具

Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool.
PubMed 文献 · Gastrointest Endosc · 2016-11-28

该研究基于澳大利亚8家三级中心2008年9月至2016年5月的前瞻性多中心数据,纳入≥20 mm分块EMR切除的侧向发育型病变,建立并验证悉尼EMR复发工具(SERT)。SERT=0病变首次监测结肠镜RRA阴性预测值91.3%,可安全推迟至18个月;SERT 1-4需6和18个月监测。

要点

  • SERT由LSL≥40 mm(2分)、术中出血(1分)、高级别上皮内瘤变(1分)构成,共4分。
  • SERT=0病变首次监测结肠镜RRA阴性预测值91.3%,可安全于18个月首次监测。
  • SERT 1-4病变需在6和18个月进行监测结肠镜。

核心结论

  • SERT能准确分层EMR术后RRA发生率,SERT=0病变可安全于18个月首次监测,SERT 1-4病变需6和18个月监测。

研究设计与样本

  • 前瞻性多中心研究,纳入澳大利亚8家三级中心2008年9月至2016年5月连续≥20 mm分块EMR切除的LSL,共1178个病变接受首次监测结肠镜。
  • 随机选取一半队列构建内镜下复发(EDR)的logistic回归模型,生成SERT 4分评分,并在剩余队列中验证。

主要发现

  • 首次监测结肠镜中位时间4.9个月(IQR 4.9-6.2),1178例中228例(19.4%)检测到EDR。
  • LSL≥40 mm(OR 2.47;P < .001)、术中出血(OR 1.78;P = .024)、高级别上皮内瘤变(OR 1.72;P = .029)为EDR独立预测因素,分别赋2、1、1分构成SERT。
  • SERT=0病变首次监测结肠镜RRA阴性预测值为91.3%,Kaplan-Meier曲线显示SERT可将RRA分层至特定随访间隔(log-rank P < .001)。

关键数值与推荐

  • 指南推荐EMR后6个月内行首次监测结肠镜(SC1)。
  • SERT=0病变可安全于18个月行首次监测。
  • SERT 1-4病变需在6和18个月行监测结肠镜。

临床怎么用

  • 根据索引EMR特征计算SERT评分以分层RRA风险:SERT=0可于18个月首次监测,SERT 1-4需6和18个月监测。
  • 指南推荐EMR后6个月内行首次监测结肠镜(SC1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: EMR is the primary treatment of large laterally spreading lesions (LSLs) in the colon. Residual or recurrent adenoma (RRA) is a major limitation. We aimed to identify a robust method to stratify the risk of RRA. METHODS: Prospective multicenter data on consecutive LSLs ≥20 mm removed by piecemeal EMR from 8 Australian tertiary-care centers were included (September 2008 until May 2016). A logistic regression model for endoscopically determined recurrence (EDR) was created on a randomly selected half of the cohort to yield the Sydney EMR recurrence tool (SERT), a 4-point score to stratify the incidence of RRA based on characteristics of the index EMR. SERT was validated on the remainder of the cohort. RESULTS: Analysis was performed on 1178 lesions that underwent first surveillance colonoscopy (SC1) (median 4.9 months, interquartile range [IQR] 4.9-6.2). EDR was detected in 228 of 1178 (19.4%) patients. LSL size ≥40 mm (odds ratio [OR] 2.47; P < .001), bleeding during the procedure (OR 1.78; P = .024), and high-grade dysplasia (OR 1.72; P = .029) were identified as independent predictors of EDR and allocated scores of 2, 1, and 1, respectively to create SERT. Lesions with SERT scores of 0 (SERT = 0) had a negative predictive value of 91.3% for RRA at SC1, and SERT was shown to stratify RRA to specific follow-up intervals by using Kaplan Meier curves (log-rank P < .001). CONCLUSIONS: Guidelines recommend SC1 within 6 months of EMR. SERT accurately stratifies the incidence of RRA after EMR. SERT = 0 lesions could safely undergo first surveillance at 18 months, whereas lesions with SERT scores between 1 and 4 (SERT 1-4) require surveillance at 6 and 18 months. (Clinical trial registration number: NCT01368289.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Tate DJ, Desomer L, Klein A, et al. Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool. Gastrointest Endosc. 2016. PMID: 27908600. doi:10.1016/j.gie.2016.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。